Oligo and Gene Production
Closed Solicitation Posted
- Solicitation number
- 75D30124Q78083
- Agency
- CDC Office of Acquisition Services Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- Place of performance
- Atlanta, Georgia, United States
- Points of contact
-
- Jennifer Gartzke xuy7@cdc.gov (404) 498-0020
Notice details come from SAM.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) Influenza Division is seeking the bulk production of oligonucleotides and synthetic genes to support the development of Candidate Vaccine Viruses (CVVs). The CDC requires 580,000 nucleotides of single-stranded DNA oligonucleotides ranging from 15-60 nucleotides in length, with a 2-business day turnaround time. This Request for Quotations (RFQ) is for a Firm-Fixed Price contract, and responses are due by August 21, 2024. The North American Industry Classification System (NAICS) code is 325414 - Biological Product (except Diagnostic) Manufacturing, and the PSC code is 6550-P - In Vitro Diagnostic Substances, Reagents, Test Kits And Sets.
This procurement is not a small business set-aside. The place of performance is Atlanta, GA, USA. There is no indication of any incumbent contractors or potential award values/budget ranges provided in the solicitation notice. The key objective is to facilitate the development of influenza CVVs, which are used as the starting materials for seasonal and pandemic vaccines.
Notice text
The Centers for Disease Control and Prevention (CDC) Influenza Division (ID) is responsible for developing Candidate Vaccine Viruses based on circulating and novel influenza strains. Candidate Vaccine Viruses (CVVs) are reassortant viruses that are used as the starting materials for seasonal and pandemic vaccines. To facilitate the development of the CVVs, CDC uses oligonucleotides and synthetic genes to transcribe the influenza genes to produce the CVVs.
During research on influenza CVVs, many different genes must be constructed, significantly more than is required in CVV production in most cases. The Influenza Division, therefore, requires bulk production of oligonucleotides with relaxed quality standards versus those required for actual CVV production. The sequences will still follow the natural evolution of viruses and, therefore, can still not be predicted.
Attachments
| File | Type | Posted |
|---|---|---|
| Amendment_00001_RFP_75D30124R72996.pdf | ||
| A19_75D301-24-Q-78083.docx | DOCX document |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity